Cabaletta Bio, Inc. (CABA)
2.91
-0.36
(-11.01%)
USD |
NASDAQ |
Sep 09, 16:00
2.96
+0.05
(+1.72%)
After-Hours: 05:41
Cabaletta Bio Shareholders Equity (Quarterly) : 210.59M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 210.59M |
| March 31, 2026 | 103.30M |
| December 31, 2025 | 112.05M |
| September 30, 2025 | 139.47M |
| June 30, 2025 | 178.48M |
| March 31, 2025 | 121.55M |
| December 31, 2024 | 152.34M |
| September 30, 2024 | 174.24M |
| June 30, 2024 | 199.52M |
| March 31, 2024 | 221.72M |
| December 31, 2023 | 236.20M |
| September 30, 2023 | 160.92M |
| June 30, 2023 | 174.14M |
| March 31, 2023 | 91.65M |
| December 31, 2022 | 104.52M |
| September 30, 2022 | 85.87M |
| Date | Value |
|---|---|
| June 30, 2022 | 95.53M |
| March 31, 2022 | 106.72M |
| December 31, 2021 | 117.96M |
| September 30, 2021 | 116.62M |
| June 30, 2021 | 101.33M |
| March 31, 2021 | 103.31M |
| December 31, 2020 | 109.54M |
| September 30, 2020 | 117.50M |
| June 30, 2020 | 124.64M |
| March 31, 2020 | 131.71M |
| December 31, 2019 | 138.32M |
| September 30, 2019 | -26.08M |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | -10.69M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
| Imunon, Inc. | 4.189M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 256.73M |
| Total Liabilities (Quarterly) | 46.14M |
| Debt to Equity Ratio | 0.1221 |
| Current Ratio | 5.789 |
| Net Debt Paydown Yield | 0.12% |